Lonza sets CHF7.5bn 2022 sales target citing pharma drivers
Lonza Group AG has predicted it will generate annual revenue of CHF7.5bn ($7.9bn) by 2022, citing recent acquisition Capsugel and its new Visp-based Ibex manufacturing service as drivers.
Archives for July 25, 2017
Sartorius takes €10m hit on media sales due to Lonza's regulatory woes
Supply chain issues stemming from an FDA warning letter at a facility run by its partner Lonza have dampened Sartorius Stedim Biotech’s first half 2017 results.
Discount dancers: Pfizer's infliximab matching Merck’s new biosimilar rival
Pfizer dropped the US price of Inflectra, its version of Johnson & Johnson's Remicade, just weeks before Merck & Co. launched its infliximab biosimilar, Renflexis.
Novartis preps production platform for alternative to Lucentis
Novartis has scaled up manufacturing of wet age-related macular degeneration (AMD) monoclonal antibody RTH258 ahead of a potential regulatory submission next year.